Association between polymorphisms of the androgen and vitamin D receptor genes with prostate cancer risk in a Mexican population

Revista de Investigacion Clinica

Volumn 59, Issue 1, 2007, Pages 25-31

  Patiño García, Brenda ^a,b   Arroyo, Carlos ^c   Rangel Villalobos, Hector ^d   Soto Vega, Elena ^e   Velarde Félix, Jose Salvador ^a,f   Gabilondo, Fernando ^g   Sandoval Ramírez, Lucila ^a   Figuera, Luis Eduardo ^a,b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^d Laboratorio de Genética Molecular

^e Hospital Regional No 36   (Spain)

^f Servicios de Salud de Sinaloa   (Mexico)

^g INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Androgen receptor; Prostate cancer genetics; Prostate cancer risk; Vitamin D receptor

Indexed keywords

ADENINE; ANDROGEN RECEPTOR; CYTOSINE; GENOMIC DNA; GUANINE; PROSTATE SPECIFIC ANTIGEN; VITAMIN D RECEPTOR;

ADULT; AGE; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA ISOLATION; EXON; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; NUCLEOTIDE REPEAT; PROGNOSIS; PROSTATE CANCER; RESTRICTION SITE; SCORING SYSTEM;

EID: 34249000980     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Dirección General de Epidemiología. Registro Histopatológico de Neoplasias Malignas, CD ©2004. www.dgepi.salud.gob.mx
2. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006: 1(11): 1388-413.
3. Ko YJ, Devi GR, London CA, Kayas A, Reddy MT, et al. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense. J Urol 2004; 172(3): 1140-4.
4. Suzuki H, Shimho M, Ichikawa T. New biomarkers for prostate cancer. Nippon Rinsho 2005; 63(2): 351-9.
5. Hakimi JM, Schoenberg MP, Rondinelli RH, Piantadosi S, Barrack ER. Androgen receptor variants with short glutamine and glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 1997; 3: 1599-608.
6. Hsing AW, Gao YT, Wu G, Wang X, Deng J, et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 2000; 60: 5111-116.
7. Mowszowicz I, Mestaver C. Mutations of the androgen receptor gene a possible role in prostate cancer. Bull Cancer 1997; 84(2): 183-8.
8. Lange EM, Chen H, Brierley K, Livermore H, Wojno KJ, et al. The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited prediposition to prostate cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 439-42.
9. n CAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in French-German population. Eur J Hum Genet 1999; 7: 357-62.
10. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, et al. Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. Saudi Med J 2004; 25(4): 447-51.
11. Bid HK, Mishra DK, Mittal RD. Vitamind-D receptor (VDR) gene (Fok-1, Taq-1 and Apa-1) polymorphisms in healthy individuals from north indian population. Asian Pac J Cancer Prev 2005; 6(2): 147-52.
12. Cheteri MB, Stanford JL, Friederichsen DM, Peters MA, Iwasaki L, et al. Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate 2004; 59(4): 409-18.
13. Correa-Cerro L, Berthon P, Haussler J, Bochum S, Drelon E, et al. Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet 1999; 105: 281-7.
14. Ntais C, Polycarpou A, Ioannidis JP. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003; 12(12): 1395-402,.
15. Macoska J. Ancestry, genetic susceptibility, E/Caqdherin160A and prostate cancer risk- is there an association? J Urol 2006; 176(2): 435-6.
16. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994; 2: 3181-6.
17. Coetzee GA, Ross RK. Re: Prostate cancer and the androgen receptor. J Natl Cancer Inst 1994; 86: 872-3.
18. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, et al. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 2000; 9: 267-74.
19. Nelson KA, Witte JS. Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 2002; 155: 883-90.
20. Yoshida KI, Yano M, Chiba K, Honda M, Kitahara S. CAG repeat length in the androgen receptor gene is enhanced in patients with idiopathic azoospermia. Urology 1999; 54: 1078-81.
21. Zitzmann M, Brune M, Kornmann B, Gromoll J, Junker R, et al. The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clin Endocrinol (Oxf) 2001; 55: 649-57.
22. Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Curan Med Surg 1998; 3: 9-15.
23. Giovannucci E, Stampfer MJ, Chan A, Krithivas K, Gann PH, et al. CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. Prostate 1999; 39: 130-4.
24. Giovannucci E, Platz EA, Stampfer MJ, Chan A, Krithivas K, et al. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology 1999; 53: 121-5.
25. Mitsumori K, Terai A, Oka H, Segawa T, Ogura K, et al. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. Prostate 1994; 41: 253-57.
26. Shibata A, Starney TA, McNeal JE, Cheng I, Peehl DM. Genetic polymorphisms in the androgen receptor and type II 5a-reductase genes in prostate enlargement. J Urol 2001; 166: 1560-4.
27. Bousema JT, Bussemakers MJ, van Houwelingen KP, Debruyne FM, Verbeek AL, et al. Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol 2000; 37: 234-8.
28. Roberts RO, Bergstralh EJ, Cunningham JM, Hebbring SJ, Thibodeau SN, et al. Androgen receptor gene polymorphisms and increased risk of urologic measures of benign prostatic hyperplasia. Am J Epidemiol 2004; 159(3): 269-76.
29. Xue W, Irvine RA, Yu MC, Ross RK, Coetze GA, et al. Susceptibility to prostate cancer: interaction beetwen genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 2000; 60: 839-41.
30. Gaston KE, Kim D, Singh S, Ford H, Mohler JL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 2003; 170; 990-3.
31. Yu H, Bharaj B, Vassilikos EJ, Giai M, Diamandis EP. Shorter CAG repeat length in the androgen receptor gene is associated with more agressive forms of breast cancer. Breast Cancer Res Treat 2000; 59: 153-61.
32. Visvanathan K, HelzIsouer KJ, Boorman DW, Strickland PT, Hoffman SC, et al. Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk. J Urol 2004; 171(2): 652-5.
33. Balic I, Graham ST, Troyer DA, Higgins BA, Pollock BH, et al. Androgen receptor length polymorphism associated with prostate cancer risk in hispanic men. J Urol 2002; 168(5): 2245-8.
34. Zhao XY, Peehl DM, Navone NM, Feldman D. 1 alpha, 25-dihydroxyvitamin D3 inhibits prostate cancer cell growth: by androgen-dependent and androgen-independent mechanisms. Endocrinology 2000; 141: 2548-56.
35. Price DK, Franks ME, Figg WD. Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism. J Urol 2004; 171(2 Suppl.): 45-9.
36. Gsur A, Madersbacher S, Haidinger G, Schatzl G, Marbegger M, et al. Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate 2002: 51(1): 30-4.
37. Paiss T, Gschwend J, Autenrieth M, Correa-Cerro, L, Haussler J, et al. Vitamin D receptor polymorphisms and prostate cancer risk in an European population. J Urol 1999; 161(4S): 56.